Life Sciences Daily Summary
Life Sciences Daily Summary: What Happened on October 5, 2026
Vaxcyte’s 31-valent vaccine clears its first Phase 3 trial
Genmab, Boehringer Ingelheim and AstraZeneca also posted trial results. Deal news included Shionogi’s $2 billion IntraBio acquisition and a $2.2 billion Bayer plant.
Today in brief
Vaxcyte said its 31-valent pneumococcal vaccine met the primary endpoints in its first of three Phase 3 trials and matched existing vaccines against nearly all strains tested.12 Genmab reported a 45.9% response rate for Rina-S in platinum-resistant ovarian cancer, and survodutide met both primary endpoints in a Phase 3 obesity and diabetes trial.345 AstraZeneca’s tozorakimab reduced COPD exacerbations in two Phase 3 trials. The FDA approved Jaypirca for some adults with untreated CLL or SLL.678
Shionogi agreed to buy IntraBio for $2 billion, CSL committed $355 million upfront to partner with Alentis, and GE HealthCare plans to acquire Sofie Biosciences for $945 million.910111213 Bayer plans a $2.2 billion Ohio manufacturing campus. Biossil raised $153 million to expand clinical development and add drug candidates.141516
Vaxcyte’s 31-valent vaccine meets endpoints in its first Phase 3 trial
Vaxcyte said VAX-31 met the primary endpoints in a Phase 3 trial of just over 3,500 adults aged 50 and older.1 The vaccine is designed to protect against 31 pneumococcal serotypes, compared with 20 for Pfizer’s Prevnar and 21 for Merck’s Capvaxive.1 In the first of three Phase 3 trials, VAX-31 matched Pfizer and Merck vaccines against nearly all bacterial strains tested.2
Genmab reports a 45.9% response rate for Rina-S in ovarian cancer
In the Phase I/II RAINFOL-01 study, Rina-S produced a confirmed response in 45.9% of 109 patients with platinum-resistant ovarian cancer, including five complete responses.34 Median response duration was 12.1 months, median progression-free survival was 9.5 months, and 51% of responders remained in response after one year.3 About one-third of participants had serious adverse events. Adverse events led 5.5% to stop treatment.34
Genmab is testing Rina-S in four Phase 3 trials covering ovarian and endometrial cancers.4
Survodutide meets both Phase 3 endpoints, with gastrointestinal events driving discontinuations
Boehringer Ingelheim’s 76-week SYNCHRONIZE-2 trial met both co-primary endpoints in 755 adults with overweight or obesity and type 2 diabetes.5 Assuming participants stayed on treatment, weight loss reached 13.1% with survodutide versus 3.1% with placebo. Up to 79.3% lost at least 5% of their weight, compared with 32.7% on placebo.5 Counting results regardless of treatment discontinuation, weight loss was 9.8% with the 6.0-mg dose and 8.2% with the 3.6-mg dose, versus 3.9% with placebo.5
Gastrointestinal events led 18% of survodutide recipients to stop treatment, compared with 1.2% of placebo recipients.5 Boehringer Ingelheim said the trial’s fixed dose-escalation approach may have contributed to those discontinuations. Newer studies allow more flexible dose increases, the company said.5 The trial did not compare survodutide with an approved incretin therapy, so its performance against those drugs remains unknown.5
Tozorakimab cuts COPD exacerbations in two Phase 3 trials
On October 1, AstraZeneca reported that tozorakimab reduced moderate-to-severe COPD exacerbation rates in OBERON and TITANIA.56 Across current and former smokers, the reductions versus placebo were 30% in OBERON and 29% in TITANIA.17 The trials enrolled 2,306 people, who received monthly treatment for 52 weeks alongside their usual inhaled medicines.17
A combined analysis found a 43% reduction among patients with blood eosinophil counts of at least 300 cells per microliter, compared with 23% among those below 150.17 The FDA is reviewing the drug, and AstraZeneca expects a decision in the first quarter of 2027.6
FDA adds Jaypirca as a first-line option for some CLL and SLL patients
The FDA approved Eli Lilly’s Jaypirca for previously untreated adults with chronic lymphocytic leukemia or small lymphocytic lymphoma who do not have a 17p deletion.78 The approval was based on BRUIN CLL-313, an open-label Phase III trial comparing Jaypirca with bendamustine plus rituximab.7 After a median 28 months of follow-up, independent review found a hazard ratio of 0.20 for progression-free survival. Median progression-free survival was not reached with Jaypirca and was 33.5 months with the comparison regimen.7
Overall response rates were 94% with Jaypirca and 81% with the comparison regimen.7 Serious adverse reactions affected 28% of Jaypirca-treated patients. Adverse events led 4.3% to stop treatment.7
Shionogi to buy IntraBio for $2 billion
Shionogi agreed to acquire IntraBio for $2 billion, adding Aqneursa, an approved treatment for neurological symptoms associated with Niemann-Pick disease type C and ataxia-telangiectasia.1112 The FDA approved Aqneursa for Niemann-Pick disease type C in 2024 and expanded its use to ataxia-telangiectasia in September 2026. It is the first approved treatment for that disorder.12 Shionogi said Aqneursa generated $67.8 million in fiscal 2025 revenue.12
The deal requires regulatory review. Shionogi expects it to close by the end of 2026.12 Aqneursa’s mechanism for treating the two conditions is unknown, according to its prescribing information.12
CSL commits $355 million upfront to partner with Alentis on lixudebart
CSL and Alentis agreed to develop and commercialize lixudebart globally. CSL will pay $355 million upfront and fund the program.910 Alentis may receive up to a further $1.2 billion in commercial milestones. If the drug reaches the market, the companies plan to split global profits 55% to CSL and 45% to Alentis.1018 The program includes a Phase III trial in AAV-associated rapidly progressive glomerulonephritis and Phase II studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis.918
In a Phase II renal study, interim results from 26 patients showed improvements in kidney-function and proteinuria measures after 24 weeks, Alentis reported.10
Bayer plans a $2.2 billion Ohio manufacturing campus
Bayer plans to invest $2.2 billion in a pharmaceutical manufacturing campus in New Albany, Ohio, for medicines in cardiovascular, cancer and kidney care.1415 The phased site is scheduled to begin drug-substance production in 2031, followed by a drug-product unit in 2034.1415 Bayer projects about 1,500 construction jobs and 600 permanent roles.15
GE HealthCare plans $945 million Sofie Biosciences acquisition
GE HealthCare plans to buy Sofie Biosciences for $945 million in cash, adding a US network that makes radiopharmaceuticals used in imaging and therapy.13 Sofie operates 15 contract manufacturing sites and 21 cyclotrons. It already works with GE HealthCare to make the cardiac imaging agent Flyrcado.13 GE HealthCare expects the deal to close in the first half of 2027. Sofie is expected to keep supplying its existing customers independently after the acquisition.13
Biossil raises $153 million to pursue drugs that failed earlier trials
Biossil raised $153 million in a round led by the OpenAI Startup Fund, with several other investors participating.16 The company acquires or licenses drugs that failed trials and reassesses whether they might work in more narrowly selected patient groups.16 Biossil said it will use the financing to expand clinical development capacity and add drug candidates.16